A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
A phase 3 trial testing ESG401 in HR-positive / HER2-negative breast cancer, now recruiting.
Overview
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT06383767, led by Qilu Pharmaceutical, and recruiting when checked on 2026-09-11. Official title: A Open-label, Randomised, Multicenter Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy. Planned enrolment is 378 participants (estimated). The study started in 2024-07-11 and primary completion is expected in 2027-06-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares ESG401, Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.